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In Latency III Epstein–Barr virus (EBV) infection, EBV nuclear
protein 2 (EBNA2) up-regulates c-myc expression to cause continuous
B-lymphocyte proliferation (Kaiser et al., 1999; Schlee et al., 2004;
Zhao et al., 2006). EBNA2 regulates virus and cell gene expression
through RBP/CSL, a sequence speciﬁc DNA binding protein that also
mediates Notch effects on gene transcription (Hayward, 2004; Kieff
and Rickinson, 2007). The structure of RBP/CSL in complex with
DNA (Kovall and Hendrickson, 2004) revealed that the protein
contained N- and C- terminal Rel-homology domains (NTD and
CTD) sandwiched around a central beta-trefoil domain (BTD). In this
and other complexes that also include portions of Notch and its co-
activator Mastermind, the NTD and BTD directly contact DNA
(Friedmann et al., 2008; Kovall and Hendrickson, 2004; Nam et al.,
2006; Wilson and Kovall, 2006). In the multiprotein-DNA complexes,the Notch RAMdomainWΦP (Φ=hydrophobic residue)motif inserts
into a hydrophobic pocket of the BTD, becoming the ﬁnal stave of
the beta-barrel-like structure. Mastermind is bound to a composite
surface formed by RBP/CSL and the Notch ankyrin repeats. EBNA2
lacks ankyrin repeat domains but binds RBP/CSL through a RAM-like
domain. A reverse yeast two-hybrid screen identiﬁed RBP/CSL BTD
residues that differentially interact with EBNA2 or Notch, but
correlative calorimetric biophysical analyses suggest that EBNA2
and Notch bind to substantially overlapping BTD sites (Fuchs et al.,
2001; Johnson et al., 2010). Thus EBNA2, like Notch, is recruited to
DNA via an interaction with the RBP/CSL BTD. However, EBNA2
lacking ankyrin repeats, does not recruit Mastermind, but instead
with its strong acidic activation domain, recruits basal and activation
related transcription factors, including HATs and citric acid lyase, an
acetyl donor (Cohen and Kieff, 1991; Tong et al., 1995a,b,c).
Remarkably, EBV nuclear proteins EBNA3A, EBNA3B, and EBNA3C,
which are turned on by EBNA2 in the initiation of B-cell proliferation,
also bind RBP/CSL (Krauer et al., 1996; Marshall and Sample, 1995;
Robertson et al., 1995, 1996a; Zhao et al., 1996). The EBNA3 proteins
may serve to limit EBNA2 activation since it lacks the ligand depen-
dence and PEST domain dependant turnover that characterize
Notch activation (Fryer et al., 2004). Indeed, the EBNA3 proteins
bind a substantial fraction of RBP/CSL in LCLs and can reduce EBNA2
Fig. 1. The EBNA3 N-termini interact strongly with RBP/CSL when expressed in
mammalian cells. (A) GST or GST-EBNA3A aa93–390 (E3A), EBNA3B aa100–400 (E3B),
EBNA3C aa101–406 (E3C) fusion proteins were expressed in E. coli, bound to
glutathione agarose and used as afﬁnity matrices to pull-down protein complexes
from lysates of 293T cells transfected with RBP/CSL-myc. After extensive washing,
puriﬁed complexes were identiﬁed by Western blotting with anti-RBP/CSL and anti-
GST antibodies (as indicated). Two percent of 293T input lysate is shown. (B) Afﬁnity
pull-down using the same GST-EBNA3 fusion proteins or GST-BLRF2 (ctrl) co-expressed
with RBP/CSL-myc in 293T cells. Puriﬁed samples were separated by SDS–PAGE and
probed by Western blotting with anti-RBP/CSL and anti-GST antibodies (as indicated).
In each case 2% of the input lysate is shown for comparison (left panels).
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et al., 1996; Waltzer et al., 1996; Zhao et al., 1996). However, at least
2–3 fold increased EBNA3A expression is necessary to inhibit EBNA2
activation of c-myc expression and stop LCL growth (Cooper et al.,
2003). The loss of RBP/CSL-DNA electromobility shifts in the presence
of EBNA3 proteins and the inability of EBNA3-VP16 activation domain
fusions to activate transcription through RBP/CSL support the
hypothesis that EBNA3 protein binding dissociates RBP/CSL from
cognate DNA (Robertson et al., 1996a,b; Waltzer et al., 1996; Zhao
et al., 1996). Since the RBP/CSL NTD and BTD contact cognate DNA,
EBNA3 disruption of RBP/CSL binding to DNA could be a consequence
of direct or indirect effects on RBP/CSL NTD or BTD.
Nevertheless, studies using LCLs expressing conditional EBNA3A
or EBNA3C indicate that EBNA3A and EBNA3C are each essential for
continued LCL growth, while EBNA3B is not, although EBNA3B does
regulate cell gene transcription (Chen et al., 2006; Maruo et al., 2003,
2006; Tomkinson and Kieff, 1992; Tomkinson et al., 1993). This argues
that EBNA3 proteins must do more than sequester RBP/CSL from
DNA, as this shared mechanism would not explain the unique
requirement for both EBNA3A and EBNA3C interaction with RBP/CSL
in maintaining LCL growth. Furthermore, any EBNA3A or EBNA3C
mutant impaired for RBP/CSL association or deﬁcient in inhibition
of EBNA2 activation of transcription through RBP/CSL, is also null for
LCL growth (Lee et al., 2009; Maruo et al., 2005, 2009). This strongly
supports the hypothesis that transcriptional regulation through RBP/
CSL is central to the role of EBNA3A and EBNA3C in LCL growth. Most
likely, RBP/CSL directly or indirectly targets EBNA3A and EBNA3C to
speciﬁc promoters to alter gene expression.
Despite the central role of RBP/CSL in EBNA3A and EBNA3C
mediated cell growth, the interaction of EBNA3A and EBNA3C with
RBP/CSL is only partially characterized and further characterization
was the impetus for the experiments reported here. A conserved
homology domain (EBNA3A aa172–220, EBNA3B aa178–226 or
EBNA3C aa182–230) (Fig. S1) is necessary for RBP/CSL interaction,
although mutations in surrounding sequences can affect EBNA3
interactions with RBP/CSL (Lee et al., 2009; Maruo et al., 2005, 2009;
West et al., 2004). Notably conserved residues in this domain do
not include the “WΦP” motif found in EBNA2 and Notch. Detailed
mapping identiﬁed EBNA3C aa181–257 as theminimal RBP/CSL binding
domain andRBP/CSL aa144–233 or aa1–181 asmediating binding to full
length EBNA3C (Zhao et al., 1996). A mammalian two-hybrid assay
demonstrated that EBNA3A aa125–222 were sufﬁcient to interact with
RBP/CSL (Dalbies-Tran et al., 2001). Alanine mutations of speciﬁc
conserved residues within the EBNA3A or EBNA3C homology domains
are null for maintaining LCL growth and abrogate EBNA3 inhibition of
EBNA2 activity in reporter assays (Dalbies-Tran et al., 2001; Lee et al.,
2009; Maruo et al., 2005, 2009; Zhao et al., 1996). However, these
mutations diminish but do not eliminate RBP/CSL binding, and some
studies suggest that this residual binding may be mediated by residues
outside of the “core” EBNA3 homology domain (Bourillot et al., 1998;
Cludts and Farrell, 1998; Dalbies-Tran et al., 2001). Because of genetic
evidence for the importance of homologydomainbinding toRBP/CSL for
LCL growth, we sought to more precisely deﬁne EBNA3A and EBNA3C
interactionswithRBP/CSL. These studies revealed aRAM-likeWTPmotif
within the EBNA3CN-terminus thatmediates strong binding to the BTD
of RBP/CSL in vitro, which surprisingly, does not appear to mediate
EBNA3C effects through RBP/CSL in LCLs.
Results and discussion
Only the EBNA3C N-terminus binds RBP/CSL robustly when bacterially
expressed
We ﬁrst identiﬁed the boundaries of EBNA3A, EBNA3B, and
EBNA3C homology on the basis of residue conservation and secondary
structure predictions as EBNA3A aa93–390, EBNA3B aa100–400, andEBNA3C aa101–406 (Fig. S1). Importantly, mutations in residues in this
broader region, but outside the homology domain, have been shown to
affect EBNA3A and EBNA3C interactions with RBP/CSL (Lee et al., 2009;
Maruoet al., 2005, 2009;West et al., 2004). Surprisingly,whenexpressed
in bacteria as GST-fusion proteins, only EBNA3C aa101–406 consistently
retrieved RBP/CSL from 293T lysates, whereas EBNA3A aa93–390 and
EBNA3B aa100–400 pulled down little or no RBP/CSL (Fig. 1A). However,
all 3 domains efﬁciently retrievedRBP/CSLwhen co-expressedwith RBP/
CSL-myc in 293T cells (Fig. 1B). Thus with the exception of EBNA3C,
binding to RBP/CSL requires mammalian expression of EBNA3 proteins,
likely due to improper folding of the domains when expressed in
bacteria, but possibly indicating a requirement for eukaryotic speciﬁc
molecular chaperones or post-translational modiﬁcations.
Mapping of the EBNA3A RBP/CSL binding domain in mammalian cells
Using a 293T cell co-expression assay, the N and C terminal extent
of the EBNA3A RBP/CSL binding domain was determined. GST-
EBNA3A aa93–390 strongly bound RBP/CSL and GST-EBNA3A
aa115–390 or 128–390 also robustly interacted albeit with slightly
reduced RBP/CSL binding, potentially due to reduced expression of
these constructs (Fig. 2, left panel). However, GST-EBNA3A aa153–
390 was substantially reduced in RBP/CSL binding, whereas GST-
EBNA3A aa167–390 failed to bind RBP/CSL. Variations in GST-EBNA3A
expression did not appear to account for this impaired binding as
both constructs were expressed at levels comparable to GST-EBNA3A
aa128–390. A GST-EBNA3A C-terminal deletion series identiﬁed an
Fig. 2. Mapping of the minimal EBNA3A RBP/CSL interacting residues. Lysates from 293T cells co-transfected with RBP/CSL-myc and a series of GST-EBNA3A fusion proteins with
sequential deletions from the N-terminus (left panels) or the C-terminus (right panels) were pulled-down with glutathione agarose. After extensive washing, samples were
separated by SDS–PAGE and probed by Western blotting with anti-RBP/CSL and anti-GST antibodies (as indicated).
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which exhibited strong binding, and GST-EBNA3A aa93–190 which
did not bind RBP/CSL (Fig. 2, right panel). Some longer constructs, e.g.
GST- aa93–269, aa93–287, or aa93–302, bound RBP/CSL weakly or
not at all, as has been previously observed (Cooper et al., 2003). These
data indicate that EBNA3A aa153–204 are a core RBP/CSL in vivo
binding domain and that N-terminal residues (aa128–152) enhance
binding, perhaps by stabilizing domain structure. EBNA3A aa153–204
includes the
199
TGLC sequence, which is critical for EBNA3A binding toFig. 3. Mapping of the minimal EBNA3C RBP/CSL interacting residues. (A) A series of N-t
expressed in E. coli, bound to glutathione agarose andmixedwith lysates from 293T cells tran
anti-RBP/CSL and anti-GST antibodies (as indicated). (B) Alignment of the N-terminal portio
(shaded) (Zhao et al., 1996). Secondary structure predictions shown above the alignment (alp
et al., 2008). Boundaries of the most informative binding constructs are shown with arrows
using color as strong (green), reduced (orange) or absent (red). Alanine mutations are sho
reporter assays and LCL growth assays (red) (Dalbies-Tran et al., 2001; Maruo et al., 2005, 2
proteins or GST alone were expressed in E. coli, bound to glutathione agarose andmixed with
were separated by SDS–PAGE and probed by Western blotting with anti-RBP/CSL and anti-RBP/CSL, for inhibition of EBNA2 transcription in transient assays, and
for LCL growth (Dalbies-Tran et al., 2001; Maruo et al., 2005).
Mapping of the EBNA3C RBP/CSL binding domain in vitro
Theminimal EBNA3Cdomain for bindingRBP/CSLwasmappedusing
a different assay that exploited the ability of GST-EBNA3C expressed in
bacteria to bind RBP/CSL. GST-EBNA3C aa164–366 efﬁciently retrieved
RBP/CSL from 293T lysates and N-terminal deletion of GST-EBNA3C toerminal (left panel) and C-terminal (right panel) GST-EBNA3C fusion proteins were
sfectedwith RBP/CSL-myc. Puriﬁed complexes were identiﬁed byWestern blotting with
ns of EBNA3A, EBNA3B, EBNA3C, including the previously identiﬁed homology domain
ha helix—cylinder; Beta sheet—block arrow) weremade with the Jpred algorithm (Cole
above (EBNA3A) or below (EBNA3C) the alignment. Strength of binding is summarized
wn in colored text as producing either no change (green) or loss of RBP/CSL activity in
009; Zhao et al., 1996). (C) EBNA3C aa164–366 wt or W227S point mutant GST-fusion
lysates from 293T cells transfected with RBP/CSL-myc. After extensive washing samples
GST antibodies (as indicated). Two percent of input lysate is shown for comparison.
22 M.A. Calderwood et al. / Virology 414 (2011) 19–25aa184 or aa211 reduced but did not eliminate RBP/CSL binding, while
further deletion to aa230 resulted in a loss of association (Fig. 3A).
Truncation from the C-terminus demonstrated that EBNA3C aa184–233
retained substantial RBP/CSL binding, suggesting critical residues
for RBP/CSL in this assay are within EBNA3C aa211–233. Surprisingly,
this excludes part of the EBNA3C
209
TFGC sequence that is critical for
EBNA3C inhibition of EBNA2 interaction with RBP/CSL in transcription
assays and for LCLgrowth (Leeet al., 2009;Maruo et al., 2009; Zhao et al.,
1996).
EBNA3C interacts with the RBP/CSL NTD and BTD via two distinct motifs
We noted that EBNA3C aa211–233 includes a WTP sequence
(Fig. 3B), which is not conserved in EBNA3A or EBNA3B and resembles
the WΦP motif within Notch (WFP) and EBNA2 (WWP) which
interacts with the RBP/CSL BTD. The potential role of the
227
WTP
sequence in mediating EBNA3C binding to RBP/CSL was evaluated
with aW227Smutation. Expressed as a GST fusion protein in bacteria,
EBNA3C aa164–366 bound RBP/CSL, while EBNA3C aa164–366W227S
was deﬁcient in RBP/CSL binding, despite equal expression levels
(Fig. 3C). This demonstrates that the
227
WTP sequence is required for
binding of bacterially expressed EBNA3C to RBP/CSL.
In mammalian cells however, EBNA3C W227S binding to RBP/CSL
was comparable to EBNA3C wild-type or
209
TFGC→AAAA (HDmut)
(Fig. 4A). Only the EBNA3C double mutant (HDmut+W227S) failed
to bind RBP/CSL. The existence of a robustly functional WΦP motif in
EBNA3C is surprising since an earlier study reported that EBNA3C
bound constructs containing the entire NTD or portions of the NTD
and BTD but failed to bind a construct containing the entire BTD and
CTD (Zhao et al., 1996). However, the exposed hydrophobic pocket
within the BTDmakes it inherently unstable (Kovall and Hendrickson,Fig. 4. The EBNA3A and EBNA3C homology domains interact with the RBP/CSL NTD. (A
(
209
TGFC→AAAA (HDmut), W227S or the double mutant HDmut+W227S) and immunopre
by Western blotting with anti-RBP/CSL and anti-EBNA3C antibodies (as indicated). One perc
full length (N+B+C), aa1–167 (N), aa147–335 (B) and aa147–486 (B+C) of RBP/CSL with
hybrid assay. Binding strength was characterized by growth on histidine minus media and
Shading in RBP/CSL schematic indicates the location of residues contributing to the NTD (g2004). Because a misfolded BTD may not exhibit proper binding to
WΦP motifs, a recent study of CSL and Notch used circular dichroism
to monitor proper construct folding (Lubman et al., 2007). To
ascertain whether the EBNA3CWTPmotif could mediate BTD binding,
we employed a yeast two-hybrid binding assay, using the Notch1
RAMdomain (aa1751–1850) as a control to assess proper BTD folding.
Indeed, one RBP/CSL construct (aa1–335) that contains the entire NTD
and BTD domains was rejected because it exhibited no biding to the
Notch1 RAM domain (data not shown). Other constructs were based
on previously characterized RBP/CSL subdomains as well as the RBP/
CSL structure (Kovall and Hendrickson, 2004; Lubman et al., 2007)
and included full length RBP/CSL (aa1–486), NTD (aa1–167), BTD
(aa147–335), and BTD plus CTD (aa147–486). Binding strength was
characterized based on growth on histidine minus media and beta-gal
positivity.Wild-type EBNA3C interacted strongly with full length RBP/
CSL and to a lesser degree with the N, B+C, and B constructs (Fig. 4B).
EBNA3C binding to the beta trefoil domain containing constructs (B
and B+C) was eliminated byW227S mutation, conﬁrming the role of
this motif as a Notch RAM-like interaction sequence in yeast. Mutation
of EBNA3C
209
TFGC→AAAA within the homology domain (HDmut)
eliminated binding to theRBP/CSLNTDbut did not impair binding to the
BTD. Importantly, EBNA3C HDmut plus W227S had only weak residual
binding to full length RBP/CSL. Thus EBNA3C appears to bind RBP/CSL
via two motifs, the homology domain targets the NTD and the WTP
motif the BTD. The EBNA3A HDmut (
199
TLGC→AAGA) also selectively
impaired binding to NTD containing constructs without effecting
binding to constructs lacking theNTD. These results aremost consistent
with a model where EBNA3 proteins target the NTD via their homology
domains but make signiﬁcant contacts with BTD or CTD through other
motifs. In the case of EBNA3C, the WTP motif targets the RBP/CSL BTD
and accounts for almost all non-homology domain binding.) 293T cells were transfected with Flag tagged EBNA3C (aa11–992) wt or mutants
cipitations performed with Flag agarose. Immunoprecipitated proteins were identiﬁed
ent of input lysate is shown for comparison. (B) Schematic summarizing interaction of
Notch1 or EBNA3A or EBNA3C wild-type or point mutants as determined by Yeast-two
beta-gal activity assay and scored as 0 none, + weak, ++ moderate or +++ strong.
ray), BTD (hatched) and CTD (black).
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To assess the signiﬁcance of WTP mediated binding for EBNA3C
function, the effect of the W227S mutation on EBNA3C's ability to
repress EBNA2 and support LCL proliferation was investigated. In
reporter gene assays, EBNA3C W227S was equivalent to EBNA3C wild-
type in repressing EBNA2 activation of Cp through RBP/CSL (Fig. 5A),
whereas EBNA3CΔ182–231 andHDmut have been previously shown to
be defective in repression of EBNA2 activation of Cp (Lee et al., 2009; Lin
et al., 2002; Maruo et al., 2009; Zhao et al., 1996). The EBNA3C W227S
was further assessed using the EBNA3C-HT LCL transcomplementation
assay in which the ability of EBNA3C mutants to maintain growth is
determined following EBNA3C-HT inactivation by withdrawal of 4HT
from the media. Consistent with prior results (Lee et al., 2009; Maruo
et al., 2009), EBNA3C-HT LCLs stopped growing after approximately
14 days in media without 4HT (Fig. 5B). When complemented with
wild-type EBNA3C or EBNA3C W227S expressed from oriP plasmids,
cells continued to grow at a rate comparable to growth in the presence
of 4HT. Western blotting for EBNA3C and EBNA3C W227S found
equivalent levels at 0 and 40 days after 4HT withdrawal, making it
unlikely that reduced binding to RBP/CSLwas overcome by selection for
increased levels of EBNA3C W227S expression. Thus, the EBNA3C WTP
motif is not required for EBNA3C transcriptional effects throughRBP/CSL
or LCL growth, despite strong effects on binding of RBP/CSL. Of the
two RBP/CSL binding elements within EBNA3C, the homology domain
through its interaction with NTD is the predominant determinant of
EBNA3C functional effects through RBP/CSL.
Concluding remarks
In summary, our ﬁnding that residues critical for RBP/CSL binding
are within EBNA3A aa128–204 is in good agreement with prior results
(Dalbies-Tran et al., 2001; Maruo et al., 2009; Zhao et al., 1996).
We have found that this domain demonstrates efﬁcient RBP/CSL
binding only when expressed in eukaryotic cells, possibly indicating a
requirement for post-translational modiﬁcations or, more likely, for
proper folding. The binding activity exhibited by EBNA3C expressed
in bacteria is attributable to a previously unrecognizedWTP sequence
that interacts with the RBP/CSL BTD. The fact that EBNA3C WTPFig. 5. Binding to RBP/CSL through the EBNA3C WTP motif is not required for repression of
with Cp-luciferase reporter construct and expression plasmids for EBNA2 and EBNA3C wild
reporter alone and were normalized for transfection efﬁciency as determined by the β-gal
independent experiments and show the standard error of the mean. Western blot of the lys
protein expression levels. (B) EBNA3C-HT LCL cells were transfected with 15 μg of the oriP
(W227S). Two days post transfection 1×106 cells were seeded in 10 ml fresh medium with (
of viable cells derived from the initial cultures were calculated and plotted at each time p
EBNA3C levels in lysates from day 0 (2 days after transfection) and day 40.mediated binding to RBP/CSL is also observed in yeast andmammalian
cells suggests that this binding is not an artifact of bacterial expression.
However, unlike the case for Notch or EBNA2, the functional impor-
tance of EBNA3C binding through thisWΦPmotif is not clear. EBNA3C
mutations that impair activity in the EBNA2 Cp repression assay fall
within EBNA3C aa160–248 which is in good agreement with
boundaries identiﬁed for EBNA3A (Fig. 3B). We propose that these
mutations abrogate binding to the RBP/CSL NTD and residual RBP/CSL
binding is attributable to the WTP motif (Fig. S2). Thus the critical
EBNA3 RBP/CSL interacting domain is approximately 80aa in size and
is predicted to fold into three beta sheet structures with an N-terminal
alpha helix that substantially enhances binding efﬁciency (Fig. 3B).
Our ﬁnding that this EBNA3 domain interacts with the RBP/CSL NTD
is consistent with an earlier study that mapped EBNA3C binding to
RBP/CSL aa1–181 (NTD) or aa144–233 (portions of the NTD and BTD)
(Zhao et al., 1996). Because the NTD is involved in binding to the
major groove, EBNA3 interaction with the NTD may explain their
ability to destabilize RBP/CSL interaction with cognate DNA. Previous
genetic studies have shown that acidic rich sequences C-terminal to
the RBP/CSL binding domain (Fig. S1) are important for EBNA3A
and EBNA3C function. Thus EBNA3 interaction with the NTD may
directly impair DNA binding or position these resides to compete
with phosphate moieties in the DNA backbone. Finally, structural
studies aiming to distinguish between these possibilities will need to
ensure that EBNA3C is expressed in such a way that homology domain
function is preserved and RBP/CSL binding is not mediated solely by
the WTP motif.
Materials and methods
Cell culture
293T, a human embryonic kidney cell line, was cultured in
Dulbecco's modiﬁed Eagle's medium (Gibco, Grand Island, NY)
supplemented with L-glutamine (Gibco), penicillin–streptomycin
(Gibco) and 10% fetalplex (Gemini Bio-Products, West Sacramento,
CA). BJAB, an EBV-negative B-lymphoma cell line, was cultured in RPMI
1640 medium (Gibco) supplemented with L-glutamine, penicillin–
streptomycin, and 10% fetalplex (R10). EBNA3C-HT LCLs (Maruo et al.,EBNA2 activation or LCL growth. (A) Reporter assay results from BJAB cells transfected
-type or W227S mutant. Luciferase activities are shown as fold activation compared to
actosidase activity. The data presented are the average of six transfections from three
ates with anti-EBNA3C antibody are shown below each graph to demonstrate EBNA3C
plasmid expressing control GFP, wild-type EBNA3C (E3C) or EBNA3C W227S mutant
+4HT) or without 4HT (−4HT). Cells were counted every 3–4 days and total numbers
oint. Data shown are representative of three experiments. Western blots demonstrate
24 M.A. Calderwood et al. / Virology 414 (2011) 19–252006) were maintained in RPMI 1640 medium supplemented with
15% fetalplex, L-glutamine, penicillin–streptomycin and 400 nM 4HT
(Sigma, St. Louis, MO).
Plasmids
EBNA3A, EBNA3B, and EBNA3C GST fusion constructs were cloned
into the pET41 vector by ligation independent cloning following the
manufacturer's instructions (Novagen, San Diego, CA). For mamma-
lian expression of GST-EBNA3 fusions, SwaI/SalI fragments were
excised from pET41 constructs and cloned into SwaI/SalI digested
pDEST27-BFLF2 (Calderwood et al., 2007). The resulting plasmids
express protein products identical to their pET41 counterparts. For
Yeast two-hybrid assays, EBNA3 or Notch open reading frames were
cloned as in-frame fusions to the gal4-DBD using the pAS construct
and RBP/CSL constructs were cloned as gal4-AD fusions using the
pACT2 vector (Lin et al., 2002). pcDNA3-CSL-myc, pLuc-Cp, pGK-βgal,
pSG5-EBNA2, pSG5-Flag-EBNA3C, and pCEP4-eGFP have been previ-
ously described (Aster et al., 1997; Lee et al., 2009; Lin et al., 2002).
EBNA3C W227S was generated by Quickchange PCR (Stratagene,
La Jolla, CA) and the mutated fragment cloned into the GST, pSG5-Flag
and pCep EBNA3C wild-type plasmids to generate appropriate point
mutants. All constructs were veriﬁed by sequencing.
Afﬁnity pulldowns
In some pulldown experiments, 293T cells were co-transfected
with 1 μg of pcDNA3-CSL-myc and 1 μg of pDEST27 expressing a GST
fusion to a portion of EBNA3A, EBNA3B, EBNA3C, or a control EBV ORF
(BLRF2) using Effectene (Qiagen, Valencia, CA). After 48 hours, cells
were lysed in NP-40 lysis buffer (1% Nonidet P40; 50 mM Tris–HCl pH
7.4; 2 mM EDTA; 150 mM NaCl) and cleared by centrifugation at
13,000g for 10 minutes. Supernatants were incubated for 2–3 hours
at 4 °C with Glutathione Sepharose (GE Healthcare, Piscataway, NJ).
The beads were washed extensively with NP-40 lysis buffer and
the proteins eluted with SDS sample buffer. In other experiments,
EBNA3GST fusion proteinswere ﬁrst expressed in BL21(DE3)pLysS RP
codon plus Escherichia coli (Stratagene) and puriﬁed using a Sarkosyl
extraction procedure (Frangioni and Neel, 1993). After extensive
washing, clariﬁed lysates from 293T cells transfected with 1 μg of
pcDNA3-CSL-myc were applied and incubated for 2–3 hours at 4 °C.
Subsequently beads were washed and eluted as in the ﬁrst procedure.
Immunoprecipitation
Transfected 293T cells were lysed in NP-40 lysis buffer containing
Complete protease inhibitor (Roche, Mannheim, Germany) and
cleared by centrifugation at 13,000g for 10 minutes. Supernatants
were incubated with anti-Flag M2 agarose (Sigma) for 2 hours at 4 °C.
The beads were extensively washed with NP-40 lysis buffer and
bound proteins eluted with 0.4 mg/ml Flag peptide (Sigma) in NP-40
lysis buffer.
Antibodies
The following antibodies were used for Western blotting: mouse
monoclonal antibody against myc (9E10); rat monoclonal against
RBP/CSL (T6709, Cosmo Bio, Tokyo, Japan);mousemonoclonal against
GST (B-14; Santa Cruz Biotechnology, Santa Cruz, CA); and mouse
monoclonal antibody against EBNA3C (A10; (Maunders et al., 1994)).
Western blot analysis
Total cell lysates or afﬁnity-precipitated proteins were separated
by SDS–PAGE, blotted onto nitrocellulose membrane, and probed
with appropriate antibodies. After extensive washing, horseradishperoxidase conjugated secondary antibodies (Jackson Immuno Re-
search, West Grove, PA) were applied and the gel developed with
chemiluminescence reagent (Perkin Elmer, Waltham, MA) and
visualized on a KODAK Image Station 4000R (Kodak Molecular
Imaging Systems, Rochester, NY).
Luciferase reporter assays
BJAB cells (~107) were transfected with 20 μg of total DNA using a
Bio-Rad Gene Pulser (Bio-Rad, Hercules, CA) at 220 V and 960 μF. Each
transfection contained 10 μg of pLuc-Cp reporter plasmid, 2 μg EBNA2
expression plasmid, 10 μg EBNA3C wild-type or point mutant, and
1 μg of pGK-βgal as a normalization control. Total plasmid DNA was
made constant by the addition of pSG5 vector DNA. After transfection,
the cells were resuspended in 15 ml of R10 and incubated at 37 °C for
48 hours. Cells were collected, washed in phosphate-buffered saline,
lysed in reporter buffer and assayed for luciferase (Luciferase Assay
System; Promega, Madison, WI) and β-galactosidase activities
(Galacto-Light Plus System; Applied Biosystems, Bedford, MA) with
an Optocomp I luminometer (MGM Instruments, Hamden, CT).
Complementation assay
Complementation assays were performed as described previously
(Lee et al., 2009). Brieﬂy, 7.5×106 EBNA3C-HT infected LCLs were
transfected with 15 μg of oriP plasmid DNA expressing E3C, E3C
W227S mutant, or control GFP oriP plasmid. Two days post
transfection 1×106 cells were seeded in 10 ml of complete medium
with or without 4HT in a 25 cm2-culture ﬂask. Every 3–7 days, cells
were counted and reseeded at the original concentration.
Yeast-two hybrid binding assay
Protein–protein interactions were assessed using a previously
described bait/prey yeast mating strategy (Calderwood et al., 2007).
Brieﬂy, pAS bait plasmids were transformed into Mav203 yeast and
baits exhibiting autoactivation as judged by growth on tryptophan and
histidine minus media supplemented with 20 mM 3-AT (Sigma) were
excluded from further analysis. Prey constructs were transformed
into Mav103 yeast. Matings were done in triplicate and strength of
interaction assessed by growth on tryptophan, leucine and histidine
minus plates supplemented with 20 mM 3-AT and by β-galactosidase
(β-gal) activity assay.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.02.018.
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